Table 6. Composition of the prognosis tissue microarray containing 12 427 prostate cancer specimens.
| No. of patients | ||
|---|---|---|
| Study cohort on tissue microarray | Biochemical relapse among categories | |
| Follow-up | ||
| n | 11 665 | 2 769 (23.7%) |
| Mean/Median (month) | 62.9/50.0 | |
| Age (y) | ||
| ≤50 | 334 | 81 (24.3%) |
| 51–59 | 3 061 | 705 (23%) |
| 60-69 | 7 188 | 1 610 (22.4%) |
| ≥70 | 1 761 | 370 (21%) |
| Pretreatment PSA (ng/ml) | ||
| <4 | 1 585 | 242 (15.3%) |
| 4–10 | 7 480 | 1 355 (18.1%) |
| 10–20 | 2 412 | 737 (30.6%) |
| >20 | 812 | 397 (48.9%) |
| pT stage (AJCC 2002) | ||
| pT2 | 8 187 | 1 095 (13.4%) |
| pT3a | 2,660 | 817 (30.7%) |
| pT3b | 1 465 | 796 (54.3%) |
| pT4 | 63 | 51 (81%) |
| Gleason grade | ||
| ≤3+3 | 2 848 | 234 (8.2%) |
| 3+4 | 6 679 | 1 240 (18.6%) |
| 3+4 Tertiary 5 | 433 | 115 (26.6%) |
| 4+3 | 1 210 | 576 (47.6%) |
| 4+3 Tertiary 5 | 646 | 317 (49.1%) |
| ≥4+4 | 596 | 348 (58.4%) |
| pN stage | ||
| pN0 | 6 970 | 1 636 (23.5%) |
| pN+ | 693 | 393 (56.7%) |
| Surgical margin | ||
| Negative | 9 990 | 1 848 (18.5%) |
| Positive | 2 211 | 853 (38.6%) |
In the column “Study cohort on tissue microarray” numbers do not always add up to 12 427 in different categories because of cases with missing data. Percent in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories. Abbreviation: AJCC, American Joint Committee on Cancer.